Inflammation and lung Cancer: the role of epithelial–mesenchymal transition
TC Walser, SJ Park, J Yanagawa… - Inflammation and lung …, 2015 - Springer
Epithelial–mesenchymal transition (EMT) is a type of cellular plasticity by which epithelial
cells acquire the form and function of mesenchymal cells. Physiologic EMT is an essential …
cells acquire the form and function of mesenchymal cells. Physiologic EMT is an essential …
Exploiting celecoxib in cancer therapy
V Jendrossek - Mitochondria: The Anti-cancer Target for the Third …, 2014 - Springer
Numerous studies demonstrate that the non-steroidal anti-inflammatory drug (NSAID)
Celecoxib is an attractive lead compound for cancer therapy: Epidemiological studies …
Celecoxib is an attractive lead compound for cancer therapy: Epidemiological studies …
The content of VEGF, COX-2 and PGE-2 in the blood serum of patients with non-small cell lung cancer with different schemes of conformal radiotherapy in the …
НА Мітряєва, ЛВ Гребіник, НВ Білозор… - Український …, 2022 - ukroj.com
Background. Overcoming radioresistance is an important problem in radiation oncology.
Therefore, the development of new approaches to modeling the radiosensitivity of tumors in …
Therefore, the development of new approaches to modeling the radiosensitivity of tumors in …
Targeted Three-Way-Junction RNA Nanoparticle Reprogrammed Cyclooxygenase-2 Catalyzed Dihomo-ϒ-Linolenic Acid Peroxidation Pattern in Lung Cancer
L Pang - 2021 - search.proquest.com
As the second most common cancer and the first leading cause of cancer deaths, lung
cancer attracts much research attention. Since cyclooxygenase-2 (COX-2) is overexpressing …
cancer attracts much research attention. Since cyclooxygenase-2 (COX-2) is overexpressing …
[PDF][PDF] Supplementary Appendix 2
DP Carbone - sage.figshare.com
Supplementary Appendix 2 Page 1 Supplementary Appendix 2 Phase 3 clinical trials and
extracted data included in the analysis Trial Primary Endpoint Positive or Negative Stage/Setting …
extracted data included in the analysis Trial Primary Endpoint Positive or Negative Stage/Setting …
[PDF][PDF] 抗悪性腫瘍薬の臨床試験における腫瘍縮小効果を考慮した全生存期間と代替エンドポイントの相関性の検討
吉田洋介, ヨシダヨウスケ - kitasato.repo.nii.ac.jp
[背景・目的] 抗悪性腫瘍薬の臨床試験において, 全生存期間 (OS) は, がん患者の臨床的
ベネフィットを示すための代表的かつ最も信頼されるエンドポイントである. 一方で, OS …
ベネフィットを示すための代表的かつ最も信頼されるエンドポイントである. 一方で, OS …
Cancer bronchique et inflammation
AM Ruppert, N Rozensztajn, T Viera, M Antoine… - Revue des Maladies …, 2015 - Elsevier
Tumor microenvironment consists in immune and inflammatory response cells, fibroblasts
and endothelial cells. Innate immunity induces inflammation and is the first non-specific line …
and endothelial cells. Innate immunity induces inflammation and is the first non-specific line …
[PDF][PDF] Dingemans
LEL Hendriks - MC, Ru sscher, DKM de, arts, M …, 2021 - scholarlypublications …
The Netherlands is a small European country with a population of 17.45 million (September
2020) distributed over 41,543 km2. 1 There are 79 hospitals (in total, 109 locations), of …
2020) distributed over 41,543 km2. 1 There are 79 hospitals (in total, 109 locations), of …
[PDF][PDF] Recent advances in vascular targeting agents as anticancer drugs
M Muyaba, Y Liu, W Si, M Xin… - … J Pharm Res, 2015 - wjpr.s3.ap-south-1.amazonaws.com
The tumor vasculature is an important target for anticancer therapy because the blood
vessels deliver oxygen and nutrients to whole-body, as well as provide a route for tumor …
vessels deliver oxygen and nutrients to whole-body, as well as provide a route for tumor …